HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ...
IBRX Sales Soar 2,540%
ImmunityBio ( NASDAQ:IBRX ) , a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue ( GAAP ) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ...
ImmunityBio ( IBRX ) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - ImmunityBio ( NASDAQ:IBRX )
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year,
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., May 15, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ...
ImmunityBio ( IBRX ) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ImmunityBio ( IBRX ) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of -25% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics ( OVID ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - ImmunityBio ( NASDAQ:IBRX )
99% 12-month and 96% 36-month disease-specific survival in papillary NMIBC without CIS. 10-year cystectomy-free status observed in long-term follow-up of Phase 1 trial. Learn the top momentum trading strategies for today's whipsaw market, live with Chris Capre on Sunday, May 4 at 1 PM ET. ...
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Guardant Health ( NASDAQ:GH ) , CNA Financial ( NYSE:CNA )
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Monday. Shares of Netflix, Inc. ( NASDAQ: NFLX fell sharply in today's pre-market trading.
ImmunityBio ( IBRX ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - Driven Brands Hldgs ( NASDAQ:DRVN ) , Hasbro ( NASDAQ:HAS )
SAN DIEGO, April 04, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: Wolfspeed, Inc. WOLF, Driven Brands Holdings Inc. DRVN, Hasbro, Inc. HAS, and ImmunityBio, Inc. IBRX.
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
MIRAMAR, Fla., March 28, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between ...
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr ( NASDAQ:CAR ) , Concentrix ( NASDAQ:CNXC )
U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday. Shares of Concentrix Corporation CNXC rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - Driven Brands Hldgs ( NASDAQ:DRVN ) , Hasbro ( NASDAQ:HAS )
SAN DIEGO, March 24, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: Wolfspeed, Inc. WOLF, Driven Brands Holdings Inc. DRVN, Hasbro, Inc. HAS, and ImmunityBio, Inc. IBRX.
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - ImmunityBio ( NASDAQ:IBRX )
HC Wainwright projects Anktiva sales to grow from $137.4 million in 2025 to $4.3 billion. ImmunityBio reported $7.21 million Q4 revenue, totaling $14.2 million in FY24. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential. Get the latest picks today before ...
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - ImmunityBio ( NASDAQ:IBRX ) , Aduro Clean Technologies ( NASDAQ:ADUR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Andrew Fein initiated coverage on ImmunityBio, Inc.
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? - SPDR S&P 500 ( ARCA:SPY )
Investors digest a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
ImmunityBio ( IBRX ) Reports Q4 Loss, Misses Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ImmunityBio ( NASDAQ:IBRX )
NEW YORK , Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc.
Cardiff Oncology ( CRDF ) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday - Andersons ( NASDAQ:ANDE ) , Analog Devices ( NASDAQ:ADI )
U.S. stocks were lower, with the Dow Jones falling over 200 points on Wednesday. Shares of Garmin Ltd. GRMN rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and FY25 outlook. It also recommended 20% dividend hike.
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Bausch Health Companies ( NYSE:BHC ) , AleAnna ( NASDAQ:ANNA )
U.S. stock futures were lower this morning, with the Dow futures falling around 500 points on Monday. Shares of Tesla, Inc. TSLA fell sharply in today's pre-market trading.
Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday - Bloom Energy ( NYSE:BE ) , CSG Systems Intl ( NASDAQ:CSGS )
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Brinker International, Inc. EAT gained 12.8% to $174.33 after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - ImmunityBio ( NASDAQ:IBRX )
On Wednesday, ImmunityBio, Inc. IBRX released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer ( NMIBC ) and non-small cell lung cancer ( NSCLC ) .
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Applied Mat ( NASDAQ:AMAT ) , Archer Aviation ( NYSE:ACHR )
U.S. stocks were lower, with the Dow Jones index falling almost 100 points on Thursday. Shares of Symbotic Inc. SYM rose sharply during Thursday's session after the company disclosed a deal to acquire Walmart Inc.'s WMT Advanced Systems and Robotics business.
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
What's Going On With ImmunityBio Shares Wednesday? - ImmunityBio ( NASDAQ:IBRX )
ImmunityBio, Inc. IBRX shares are trading lower on Wednesday after the company announced the pricing of its offering of 33,333,334 shares at $3.00 each.
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Bausch & Lomb ( NYSE:BLCO ) , Hershey ( NYSE:HSY )
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday. Shares of Macy's, Inc. M fell sharply in today's pre-market trading after the company reported third-quarter financial results and lowered FY24 EPS outlook.
Wall Street Analysts Think ImmunityBio ( IBRX ) Could Surge 184.43%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
Press release for Q3 2024 business highlights and financial results ...
ImmunityBio ( IBRX ) Reports Q3 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 22.22% and 39.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. ( TCRX ) Reports Q3 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 10.71% and 63.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q3 Loss, Lags Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -14.29% and 21.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Oculis Holding AG ( OCS ) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -5.77% and 11.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of 8.75% and 2.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
2 Stocks to Watch After New Analyst Coverage
The recent surge in analyst coverage for stocks such as EGBN and IBRX indicates the potential for significant price appreciation in the near term.
Vir Biotechnology, Inc. ( VIR ) Reports Q3 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -62.50% and 72.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ImmunityBio ( NASDAQ:IBRX )
NEW YORK, Oct. 30, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc.
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation PRCT rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Koninklijke Philips ( NYSE:PHG )
Shares of LENZ Therapeutics, Inc. LENZ rose sharply in today's pre-market trading. CORXEL and LENZ Therapeutics revealed topline data from China Phase 3 Presbyopia trial of LNZ100. LENZ Therapeutics shares jumped 18% to $31.88 in the pre-market trading session.
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday - Booz Allen Hamilton ( NYSE:BAH )
U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Booz Allen Hamilton Holding Corporation BAH rose sharply during Friday's session after the company reported better-than-expected quarterly EPS and sales.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - ImmunityBio ( NASDAQ:IBRX )
As of Oct. 25, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Deckers Outdoor ( NYSE:DECK )
Shares of Deckers Outdoor Corporation DECK rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results. Deckers reported second-quarter revenue of $1.31 billion, beating analyst estimates of $1.2 billion.
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - ImmunityBio ( NASDAQ:IBRX )
EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases.
Texas Instruments Posts Strong Q3 Results, Joins Valmont Industries, Lithia Motors, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday - Texas Instruments ( NASDAQ:TXN )
U.S. stocks were lower, with the Dow Jones index falling around 200 points on Wednesday. Shares of Texas Instruments Incorporated TXN rose sharply during Wednesday's session following better-than-expected third-quarter financial results.
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" - Genenta Science ( NASDAQ:GNTA )
MILAN and NEW YORK, Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- Genenta Science GNTA, a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Strategies in the ...
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Champions Oncology ( NASDAQ:CSBR )
Shares of Champions Oncology, Inc. CSBR rose sharply in today's pre-market trading reported better-than-expected financial results for the first quarter on Wednesday. The company reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of a loss of $0.3 per share.
